Crossmark

Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial

Crossref DOI link: https://doi.org/10.1016/j.repc.2025.12.010

Published Print: 2026-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aguiar-Neves, Inês

Diaz, Sílvia O.

Pedro Ferreira, João

Girerd, Nicolas

Pellicori, Pierpaolo

Mariottoni, Beatrice

Cosmi, Franco

Hazebroek, Mark

Verdonschot, Job A.J.

Cuthbert, Joe

Petutschnigg, Johannes

Heymans, Stephane

Staessen, Jan A.

Pieske, Burkert

Edelmann, Frank

Clark, Andrew L.

Rossignol, Patrick

Fontes-Carvalho, Ricardo

Cleland, John G.

Zannad, Faiez
Funding

Funding for this research was provided by:

European Regional Development Fund (NORTE-01-0145-FEDER-000039)

European Commission

European Commission Seventh Framework Programme for Research and Technological Development Health (305507)
License Information

Text and Data Mining valid from 2026-05-01

Text and Data Mining valid from 2026-05-01

Version of Record valid from 2026-03-20
More Information

This article is maintained by: Elsevier

Article Title: Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial

Journal Title: Revista Portuguesa de Cardiologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.repc.2025.12.010

Content Type: article

Copyright: © 2026 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U.